Relative to doctors who were shown rational ads that were generalized, the third annual Wunderman Thompson Health Inertia Study found that 34 percent more doctors were likely to take action after seeing emotional ads that addressed them on a personal level.
The U.S. FDA approved a bone-building drug from Pfenex Inc. to treat osteoporosis in certain patients at high risk for fractures, marking the company’s first commercial product.
The U.S. Supreme Court on Monday handed a victory to Merck & Co. – at least for now – by throwing out a lower court ruling that had revived hundreds of lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking the osteoporosis drug Fosamax.
Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.
Amgen and UCB announced that the U.S. FDA approved Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
An advisory panel to the U.S. FDA said benefits of Amgen Inc.’s osteoporosis treatment for postmenopausal women at high risk for fracture outweighed the monthly injection’s risks.
Amgen and UCB announced the resubmission of the Biologics License Application to the U.S. FDA for Evenity (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
The U.S. Supreme Court agreed to hear Merck & Co.’s appeal of a lower court’s ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.
Very few U.S. adults receive all the preventive health care services recommended for them, reports a new study.
Amgen today announced that the European Commission approved a new indication for Prolia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.